374 reports of this reaction
1.2% of all BENDAMUSTINE HCL reports
#20 most reported adverse reaction
BLOOD LACTATE DEHYDROGENASE INCREASED is the #20 most commonly reported adverse reaction for BENDAMUSTINE HCL, manufactured by Meitheal Pharmaceuticals Inc.. There are 374 FDA adverse event reports linking BENDAMUSTINE HCL to BLOOD LACTATE DEHYDROGENASE INCREASED. This represents approximately 1.2% of all 30,914 adverse event reports for this drug.
Patients taking BENDAMUSTINE HCL who experience blood lactate dehydrogenase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD LACTATE DEHYDROGENASE INCREASED is a less commonly reported adverse event for BENDAMUSTINE HCL, but still significant enough to appear in the safety profile.
In addition to blood lactate dehydrogenase increased, the following adverse reactions have been reported for BENDAMUSTINE HCL:
The following drugs have also been linked to blood lactate dehydrogenase increased in FDA adverse event reports:
BLOOD LACTATE DEHYDROGENASE INCREASED has been reported as an adverse event in 374 FDA reports for BENDAMUSTINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD LACTATE DEHYDROGENASE INCREASED accounts for approximately 1.2% of all adverse event reports for BENDAMUSTINE HCL, making it a notable side effect.
If you experience blood lactate dehydrogenase increased while taking BENDAMUSTINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.